Thursday, 28 May 2020
The News and Media Division of The Insight Partners
Tuesday, 19 May 2020 02:00 pm

Enzychem Lifesciences Appoints Duke Medical Coronavirus Task Force Expert Dr. Cameron Wolfe to Lead Development of EC-18 as a COVID-19 Therapeutic Drug

Dr. Wolfe has been leading Duke University Medical School's Coronavirus Task Force, where he has been on the frontlines treating COVID-19 patients.


Enzychem Lifesciences, a global biopharmaceutical company focusing on innovative new drug development for unmet medical needs, announced that Dr. Cameron Robert Wolfe, associate professor of medicine at Duke University School of Medicine, an internationally renowned specialist in infectious diseases, has been appointed to lead the Company's U.S COVID-19 efforts of the development of EC-18 as a COVID-19 therapeutic drug. 

Dr. Wolfe has been leading Duke University Medical School's Coronavirus Task Force, where he has been on the frontlines treating COVID-19 patients.

He is a nationally recognized infectious disease expert, specializing in HIV infection, transplant-related infectious diseases, general infectious diseases, biological and emergency preparedness for hospital systems, influenza and respiratory viral pathogens. He conducted his fellowship in infectious diseases at Duke University School of Medicine, and his M.B.B.S from the University of Melbourne. He is currently an investigator on the Phase 3 study for Remdesivir (GS-5734) in severe COVID-19 participants, a Phase 3 study of Remdesivir in Moderate COVID-19 patients, the Adaptive COVID-19 Treatment Trial (ACTT), and the CARE Focus 1: Latency Biomarker Project.

"We are honored to have Dr. Wolfe, an internationally recognized expert in infectious diseases, who is currently conducting numerous research studies on COVID-19, to lead our U.S COVID-19 efforts," said Ki Young Sohn, Chairman & CEO of Enzychem Lifesciences. "With his extensive experience in COVID-19, Dr. Wolfe will be able to provide high-level guidance and counsel to our scientific team, as we prepare our lead compound, EC-18, as a potential treatment for Acute Respiratory Distress Syndrome (ARDS) in COVID-19, and development plan more broadly in other infectious diseases."

"I look forward to working with Chairman Sohn and the rest of the Enzychem Lifesciences team to develop EC-18, a promising candidate with the potential to treat not only ARDS and COVID-19 related complications, but as a potential therapy for other infectious diseases. EC-18 has activity in a wide-range of indications, and I look forward to working with the team as we advance EC-18," said Dr. Wolfe.  

Tags Duke Medical Enzychem Lifesciences COVID-19 Therapeutic Drug COVID-19 Biopharmaceutical

Neha Pandey

Aware of her elements, Neha writes the best articles across industries including electronics & semiconductors, automotive & transportation and food & beverages. Being from the finance background she has the ability to understand the dynamics of every industry and analyze the news updates to form insightful articles. Neha is an energetic person interested in music, travel, and entertainment. Since past 5 years, she written extensively on sectors like technology, finance and healthcare.

Smarter Decisions with Smart News

Smart Market News is committed to getting its readers the latest updates and insights on industries that help in making “smarter” business decisions. With insights and inputs from corporate decision makers, we bring you the stories of adopting innovative solutions and strategies that have been changing the world. Our editorial insights on products, solutions, companies, and adoption of best practices not only help in understanding the markets better, but also prove to be a complete package for your information needs.

media@smartmarketnews.com | sales@smartmarketnews.com

Contact Us
Subscribe to our newsletter
Get the latest in your inbox weekly Sign up for the fully charged newsletter
Follow Us:
© The News and Media Division of The Insight Partners 2019 | All Rights Reserved | Privacy Policy